Joseph Gulfo named executive director of the Rothman Institute at Fairleigh Dickinson University

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JOSEPH GULFO was named executive director of the Rothman Institute of Innovation and Entrepreneurship at Fairleigh Dickinson University.

The university also launched the Initiative for Patient Centered Innovation, to be led by Gulfo, in collaboration with the School of Pharmacy’s Center for Healthcare Innovation and Technology. Among the programs to be undertaken include the Medical Innovation Impact Index, shadow advisory committee panels, and audits of regulations and guidance documents.

Gulfo is the author of Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances and a contributor to Inc.com. He has more than 25 years of experience in the pharmaceutical and medical device industries and received the American Business Awards Maverick of the Year Award in 2012. He also teaches graduate courses on strategic innovation management in FDU’s MBA program.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login